CBAY News and Press, CymaBay Therapeutics Inc. From 11/19/23

2023-11-19 09:52:24 ET Summary Today, we revisit CymaBay Therapeutics, a clinical stage biopharma company focused on developing therapies for liver and chronic diseases. The company's primary product candidate, seladelpar, has shown positive results in treating primary biliary cho...

2023-11-15 07:00:00 ET Summary Biotech stocks, long burdened by concerns over rising yields, are poised for improvement as the 10-year yield may have peaked, signaling a potential upswing in the industry's fortunes. The recent uptrend in the 10-year yield, peaking around 5% in Oct...

CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting® PR Newswire 61.7% of patients on seladelpar 10 mg achieved the primary composite endpoint vs. 20.0% of patients on...

2023-11-10 14:55:59 ET More on CymaBay CymaBay Therapeutics, Inc. (CBAY) Q3 2023 Earnings Call Transcript CymaBay: Positive Phase 3 Data And Competitive Advantage Established CymaBay Therapeutics: Shares Jump On Confirmatory Seladelpar Data - As Good As It Gets? ...

2023-11-07 23:21:03 ET CymaBay Therapeutics, Inc. (CBAY) Q3 2023 Earnings Conference Call November 07, 2023 04:30 PM ET Company Participants Paul Quinlan - General Counsel Sujal Shah - Chief Executive Officer Chuck McWherter - Chief Scientific Officer & Presi...

2023-11-07 16:25:02 ET More on CymaBay Therapeutics CymaBay: Positive Phase 3 Data And Competitive Advantage Established CymaBay Therapeutics: Shares Jump On Confirmatory Seladelpar Data - As Good As It Gets? CymaBay Therapeutics, Inc. (CBAY) Q2 2023 Earnings Call Tr...

Announced top-line results from RESPONSE Phase 3 study in PBC where seladelpar met the primary and two key secondary endpoints with high statistical significance. Seladelpar granted revised Breakthrough Therapy Designation for the treatment of PBC including pruritus in patients without ...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

CymaBay Therapeutics Inc. (CBAY) is expected to report $-0.3 for Q3 2023

NEWARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that two-year safety and efficacy results of seladelpar for primary biliary ...